Predicting Infection Risk in Multiple Sclerosis Patients Treated with Ocrelizumab: A Retrospective Cohort Study

BACKGROUND: Ocrelizumab safety outcomes have been well evaluated in clinical trials and open-label extension (OLE) studies. However, risk factors for infection in patients with multiple sclerosis (MS) receiving ocrelizumab have not been extensively studied in the real-world setting. OBJECTIVE: The a...

Descripción completa

Detalles Bibliográficos
Autores principales: Seery, Nabil, Sharmin, Sifat, Li, Vivien, Nguyen, Ai-Lan, Meaton, Claire, Atvars, Roberts, Taylor, Nicola, Tunnell, Kelsey, Carey, John, Marriott, Mark P., Buzzard, Katherine A., Roos, Izanne, Dwyer, Chris, Baker, Josephine, Taylor, Lisa, Spriggs, Kymble, Kilpatrick, Trevor J., Kalincik, Tomas, Monif, Mastura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042832/
https://www.ncbi.nlm.nih.gov/pubmed/33847902
http://dx.doi.org/10.1007/s40263-021-00810-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8042832/
https://www.ncbi.nlm.nih.gov/pubmed/33847902
http://dx.doi.org/10.1007/s40263-021-00810-3

Ejemplares similares